Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
A phase-II study of ifosfamide with mesna, given intravenously daily for five days by bolus injection, has demonstrated the activity of ifosfamide against a spectrum of childhood malignant solid tumors. Ifosfamide presently is being investigated in alternative phase-I schedules, daily times three or every other day times three with the aim of delivering comparable amounts of ifosfamide without increasing toxicity--specifically, neurotoxicity. Additionally, response following ifosfamide treatment is being evaluated for previously untreated children with osteosarcoma and rhabdomyosarcoma after 6 weeks of treatment, and for previously untreated patients with Ewing's sarcoma after 9 weeks of treatment with ifosfamide/VP-16 (etoposide) given in combination.
Pratt
C B
CB
Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN 38101.
Douglass
E C
EC
Etcubanas
E
E
Goren
M P
MP
Green
A A
AA
Hayes
F A
FA
Horowitz
M E
ME
Meyer
W H
WH
Thompson
E I
EI
Wilimas
J A
JA
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000008:administration & dosage*; D009369:Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D012509:Sarcoma / Q000188:drug therapy
D008623:Mercaptoethanol; D015080:Mesna; D007069:Ifosfamide